Form 8-K - Current report:
SEC Accession No. 0001411685-25-000048
Filing Date
2025-06-25
Accepted
2025-06-25 16:59:22
Documents
15
Period of Report
2025-06-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtgn-20250623.htm   iXBRL 8-K 28516
2 EX-10.1 vtgn20250623ex101.htm EX-10.1 61001
3 EX-99.1 vtgn20250623ex991.htm EX-99.1 16673
7 image.jpg GRAPHIC 9747
  Complete submission text file 0001411685-25-000048.txt   255372

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtgn-20250623.xsd EX-101.SCH 1785
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtgn-20250623_lab.xml EX-101.LAB 21629
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtgn-20250623_pre.xml EX-101.PRE 12510
17 EXTRACTED XBRL INSTANCE DOCUMENT vtgn-20250623_htm.xml XML 2729
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

EIN.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 251074289
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)